Norway Pharmaceuticals & Healthcare Q1 2019
Ongoing efforts by Norway and Denmark to jointly negotiate the price of selected medicines pose downside risks todrugmakers seeking to launch an innovative medicine in these countries' pharmaceutical markets. In fact, Norway's stringent drugpricing policies will continue to limit drugmaker opportunities, despite sustained market growth. On the upside, an ageingpopulation and the rising demand for chronic disease treatment underpin market growth fundamentals, which will be supported byhigh expenditure on healthcare.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook